- United States
- /
- Biotech
- /
- NasdaqGS:ALKS
Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings
Soft earnings didn't appear to concern Alkermes plc's (NASDAQ:ALKS) shareholders over the last week. We did some digging, and we believe the earnings are stronger than they seem.
The Impact Of Unusual Items On Profit
For anyone who wants to understand Alkermes' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by US$48m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If Alkermes doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Alkermes' Profit Performance
Unusual items (expenses) detracted from Alkermes' earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Alkermes' statutory profit actually understates its earnings potential! On the other hand, its EPS actually shrunk in the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Every company has risks, and we've spotted 2 warning signs for Alkermes (of which 1 can't be ignored!) you should know about.
Today we've zoomed in on a single data point to better understand the nature of Alkermes' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:ALKS
Alkermes
A biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Fair value with moderate growth potential.
Similar Companies
Market Insights
Weekly Picks

Looking to be second time lucky with a game-changing new product

Second order memory play likely to double in a year

Intuitive Machines: To The Moon and Beyond!
AppLovin’s AI Engine Is Printing Profit
Recently Updated Narratives

Kraft Heinz (KHC): Less Drama, More Ketchup

Compounding capital through cutting-edge DeFi

Kazatomprom is uniquely positioned to capture structural upside
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality
NVIDIA will see a profit margin surge of 55% in the next 5 years
